Amgen

FDA ends busy year with three drug rejections
BioPharma Dive
Tue, 01/2/24 - 10:13 pm
FDA
Amgen
Zealand Pharma
Merck
Amgen's request for full approval of Lumakras in lung cancer denied by FDA
Fierce Pharma
Wed, 12/27/23 - 11:02 pm
Amgen
Lumakras
FDA
non-small cell lung cancer
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
Pharmaphorum
Thu, 12/14/23 - 09:34 am
Amgen
tarlatamab
small cell lung cancer
bispecifics
BiTE
solid tumors
Amgen expands pact with Amazon to usher drug manufacturing into the AI era
Fierce Pharma
Wed, 11/29/23 - 12:06 pm
Amgen
artificial intelligence
Amazon
drug manufacturing
PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence
PR Newswire
Thu, 11/16/23 - 10:18 am
Amgen
PostEra
artificial intelligence
drug discovery
Amgen reports data from Sjögren’s Syndrome treatment trial
Clinical Trials Arena
Wed, 11/8/23 - 10:18 am
Amgen
clinical trials
dazodalibep
Sjögren’s syndrome
Amgen scores FDA approval for Stelara biosimilar
Pharmaceutical Technology
Wed, 11/1/23 - 10:16 pm
Amgen
Stelara
biosimilars
JNJ
FDA
Wezlana
'This field is in its infancy': Amgen noncommittal on oral obesity med until phase 1 data arrive
Fierce Biotech
Wed, 11/1/23 - 10:17 am
Amgen
obesity
AMG-786
Amgen stops trial of Teneobio cancer candidate, taking $650M BiTE out of earnings
Fierce Biotech
Tue, 10/31/23 - 10:19 am
Amgen
earnings
Teneobio
bispecifics
Amgen plans to lay off 350 former Horizon employees after $28B buyout
Fierce Pharma
Tue, 10/24/23 - 07:54 pm
Amgen
Horizon Therapeutics
layoffs
M&A
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Mon, 10/23/23 - 10:30 am
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
BioSpace
Fri, 10/20/23 - 11:34 am
Amgen
bispecific antibodies
T-cell engager
tarlatamab
clinical trials
Amgen Completes $27.8B Horizon Acquisition Following FTC Challenge
BioSpace
Fri, 10/6/23 - 11:37 am
Amgen
Horizon Therapeutics
FTC
M&A
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Thu, 10/5/23 - 09:13 pm
Amgen
Lumakras
FDA
KRAS inhibitors
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
BioSpace
Wed, 10/4/23 - 11:08 am
Amgen
Lumakras
non-small cell lung cancer
FDA
FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug
Reuters
Tue, 10/3/23 - 10:23 am
Amgen
FDA
Lumakras
lung cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Proactive Investors
Thu, 09/28/23 - 10:42 am
Amgen
Neumora
IPOs
Amgen unveils Partners of Choice oncology network
Medical Marketing and Media
Thu, 09/21/23 - 06:35 pm
Amgen
expert panels
oncology
cancer
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
BioSpace
Wed, 09/20/23 - 08:59 am
Amgen
Horizon Therapeutics
FTC
antitrust
M&A

Pages